A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-03. Anything still debated is marked as such rather than presented as settled.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
== See also == All pages with titles beginning with Combine All pages with titles containing Combine Combination (disambiguation) Combined (disambiguation) Combiner CombineZ, image processing software Merge (disambiguation) Unite (disambiguation)
=== "One Strike and You're Out" policy" === Scholars have argued that Clinton's policies came in an attempt to swing back the tide of white voters who had left the party two decades earlier to support Reagan. The Clinton administration articulated that the policies were an attempt to be fiscally conservative and to slash the federal budget deficit. During the administration, the federal budget saw a reduction in public housing funding by $17 billion. The federal corrections programs received a $19 billion, which a 61 percent decrease in public housing funding and a 171 percent increase in federal prison budgeting. Scholars argue that the construction of federal prisons replaced the major public housing programs for the urban poor. Clinton's "One Strike and You're Out" policy stated, "From now on, the rule for residents who commit crime and peddle drugs should be one strike and you're out." Any tenant of public housing convicted of any drug-related offence would no longer have access to public housing.
== Fifth Ministry == On 13 September 2006, following the 2006 election, a ministry of 19 cabinet ministers and 11 parliamentary secretaries was sworn in. It served until the end of the Ministry on 13 September 2007 following Anna Bligh's ascension to the post of Premier, and was followed by the Bligh Ministry. Linda Lavarch, the Attorney-General, resigned from the Ministry on 18 October 2006 citing depression. Kerry Shine and Margaret Keech assumed her portfolios on 1 November 2006. Craig Wallace was appointed to the available place within the Ministry.
== Redox reactions in industry == Cathodic protection is a technique used to control the corrosion of a metal surface by making it the cathode of an electrochemical cell. A simple method of protection connects protected metal to a more easily corroded "sacrificial anode" to act as the anode. The sacrificial metal, instead of the protected metal, then corrodes. Oxidation is used in many industries, such as in the production of cleaning products and oxidizing ammonia to produce nitric acid, whose principal industrial route is the catalytic oxidation of ammonia in the Ostwald process. Redox reactions are the foundation of electrochemical cells, which can generate electrical energy or support electrosynthesis. Metal ores often contain metals in oxidized states, such as oxides or sulfides, from which the pure metals are extracted by smelting at high temperatures in the presence of a reducing agent. The process of electroplating uses redox reactions to coat objects with a thin layer of a material, as in chrome-plated automotive parts, silver plating cutlery, galvanization and gold-plated jewelry.
Bill Pittendreigh, DuPont, and other individuals and corporations worked diligently during the first few months of World War II to find a way to replace Asian silk and hemp with nylon in parachutes. It was also used to make tires, tents, ropes, ponchos, and other military supplies. It was even used in the production of a high-grade paper for U.S. currency. At the outset of the war, cotton accounted for more than 80% of all fibers used and manufactured, and wool fibers accounted for nearly all of the rest. By August 1945, manufactured fibers had taken a market share of 25%, at the expense of cotton. After the war, because of shortages of both silk and nylon, nylon parachute material was sometimes repurposed to make dresses. Nylon 6 and 66 fibers are used in carpet manufacture. Nylon is one kind of fiber used in tire cord. Herman E. Schroeder pioneered application of nylon in tires.
Sources: en.wikipedia.org
Some PCR fingerprint methods have high discriminative power and can be used to identify genetic relationships between individuals, such as parent-child or between siblings, and are used in paternity testing (Fig. 4). This technique may also be used to determine evolutionary relationships among organisms when certain molecular clocks are used (i.e. the 16S rRNA and recA genes of microorganisms).
The history of the Soviet Union began with the ideals of the Bolshevik Revolution and ended in dissolution amid economic collapse and political disintegration. Established in 1922 following the Russian Civil War, the Soviet Union became a one-party state under the Communist Party. Its early years under Lenin were marked by the implementation of socialist policies and the New Economic Policy (NEP), which allowed for market-oriented reforms. The rise of Joseph Stalin in the late 1920s ushered in an era of intense centralization and totalitarianism. Stalin's rule was characterized by the forced collectivization of agriculture, rapid industrialization, and the Great Purge, which eliminated perceived enemies of the state. The Soviet Union, one of the Big Four Allied powers alongside the United States, the United Kingdom, and China, played a crucial role in the Allied victory in World War II. It paid a tremendous human cost with millions of Soviet citizens dying in the conflict. The Soviet Union emerged as one of the world's two superpowers, leading the Eastern Bloc in opposition to the Western Bloc during the Cold War. This period saw the USSR engage in an arms race, the Space Race, and proxy wars around the globe. The post-Stalin leadership, particularly under Nikita Khrushchev, initiated a de-Stalinization process, leading to a period of liberalization and relative openness known as the Khrushchev Thaw.
==== Rocker Deformity ==== When operating on the upper vault of the nose, osteotomies may be performed to mobilize the nasal bones. These osteotomies should ideally have their superior limit at the nasofrontal suture, which is approximated by the medial canthus. If the osteotomy is carried too far superiorly into the frontal bone, a Rocker deformity may result, wherein the upper portion of the mobile bone flares outwards (or "rocks") when the inferior portion is medialized. Correction of a Rocker deformity would involve a transverse percutaneous osteotomy.
== External links == DASH7 Alliance Low Power Wide Area Network Technology Comparison OSS-7 Open Source Stack Archived 2019-12-24 at the Wayback Machine OpenTag wiki Archived 2019-12-06 at the Wayback Machine DASH7-LoRaWAN Comparison
In Mexico a vigilante group called Grupos de autodefensa comunitaria was formed to counter the illegal loggers, the La Familia Michoacana Cartel and a drug cartel/cult known as the Knights Templar Cartel; as they grew, they were being joined by former cartel members and as they got bigger they began to sell drugs in order to buy weapons. The Knights Templar Cartel was eventually defeated and dissolved by the vigilantes' actions but they ended up forming their own cartel called Los Viagras, which has links with the Jalisco New Generation Cartel. The Minuteman Project is a far-right paramilitary organization that seeks to prevent illegal immigration across the US-Mexico border; however, doing so is detrimental to gangs like Mara Salvatrucha (MS-13), who make money through people smuggling, and as a result MS-13 is known to commit acts of violence against members of the Minutemen, to prevent them from interfering with their illegal immigration activities. Throughout the world there are various anti-gang vigilante groups, who profess to be fighting against gang influence, but share characteristics and acts similarly to gangs, including Sombra Negra, Friends Stand United, People Against Gangsterism and Drugs, and OG Imba. Gangs that are involved in drug trafficking often commit violent acts to stop or force out independent dealers—drug dealers with no gang ties—to keep them from taking customers.
Sources: en.wikipedia.org
The proportion of AST to ALT in hepatocytes is about 2.5:1, but because AST is removed from serum by the liver sinusoidal cells twice as quickly (serum half-life t1/2 = 18 hr) compared to ALT (t1/2 = 36 hr), so the resulting serum levels of AST and ALT are about equal in healthy individuals, resulting in a normal AST/ALT ratio around 1. An AST/ALT ratio >5 necessarily involves extrahepatic tissue, as death of hepatocytes alone would produce an AST/ALT ratio no greater than 2.5. Because the primary cause is extrahepatic, typically an isolated elevated AST is seen, with no change in ALT. Common causes include bone disease, chronic renal failure, lymphoma, and congestive heart failure. When hepatocellular death is increased beyond the usual "background" levels, the serum levels of AST compared to ALT tend to reflect the cellular proportions, yielding AST that is over twice as prevalent as ALT (AST/ALT >2) in conditions with chronic, constant hepatocyte damage (such as alcoholic hepatitis, hepatocellular carcinoma) and during early-stage acute liver damage (such as viral hepatitis). In late-stage acute liver damage, the body has had adequate time to clear AST, but not ALT, often resulting in an AST/ALT <1. Since testing typically occurs late in acute viral hepatitis, it is conventionally associated with an AST/ALT ratio <1, though early in the disease, the AST/ALT ratio is often elevated. As the acute liver damage resolves, the body has more time to clear ALT, so in the absence of chronic liver disease, the AST/ALT ratio gradually returns to baseline levels.
== International Mass Spectrometry Foundation == The major awards from the International Mass Spectrometry Foundation are the Thomson Medal Award, the Curt Brunnée Award, and the Jochen Franzen Award.
== History == In the 1930s, hydrocortisone was found by biochemist Edward C. Kendall and rheumatologist Philip S. Hench, who were both Nobel laureates. When they were investigating therapies for rheumatoid arthritis, they discovered that female patients of the disease would experience an alleviation of their condition if they were pregnant at the same time. It was also found that patients suffering from both rheumatoid arthritis and jaundice would have fewer symptoms associated with rheumatoid arthritis. Following this finding, they extracted different hormones from the adrenal cortex of cows in search of a suitable drug. They first identified cortisone to be one of the possible drugs, and further research led them to discover an effective drug for human dermal problems, which was hydrocortisone. After the discovery of hydrocortisone, the earliest application of hydrocortisone as a topical form in humans was recorded in 1952. Its successful utilization facilitated more research on topical corticosteroids, which helped the development of similar drugs with higher activity.
== Description == Most cases of feline hypersomatotropism are caused by acidophilic pituitary tumours that predominantly secrete growth hormone. In some cases low levels of other pituitary hormones are secreted. Rarely a cat may have double adenomas. In a few cases the diagnosis has been pituitary acidophilic hyperplasia. In dogs nearly all cases of acromegaly are caused by endogenous or exogenous progestogens, this causes a hypersecretion of growth hormones from the mammary gland. Pituitary tumours causing excess growth hormone secretion are very rare in dogs.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.